Colgate-Palmolive Company $CL Shares Acquired by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. lifted its position in shares of Colgate-Palmolive Company (NYSE:CL) by 5.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 235,865 shares of the company’s stock after purchasing an additional 12,075 shares during the period. Braun Stacey Associates Inc.’s holdings in Colgate-Palmolive were worth $20,103,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of CL. Brighton Jones LLC increased its holdings in shares of Colgate-Palmolive by 4.4% in the 4th quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock valued at $962,000 after acquiring an additional 450 shares during the last quarter. Woodline Partners LP raised its position in shares of Colgate-Palmolive by 76.3% during the 1st quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock worth $4,344,000 after acquiring an additional 20,062 shares in the last quarter. Schnieders Capital Management LLC. lifted its stake in Colgate-Palmolive by 2.0% during the second quarter. Schnieders Capital Management LLC. now owns 12,494 shares of the company’s stock worth $1,136,000 after purchasing an additional 245 shares during the last quarter. Nebula Research & Development LLC boosted its holdings in Colgate-Palmolive by 165.5% in the second quarter. Nebula Research & Development LLC now owns 10,326 shares of the company’s stock valued at $939,000 after purchasing an additional 6,437 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Colgate-Palmolive by 21.7% in the second quarter. Sei Investments Co. now owns 657,093 shares of the company’s stock valued at $59,732,000 after purchasing an additional 116,968 shares in the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.

Colgate-Palmolive Trading Up 1.1%

CL opened at $92.06 on Friday. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 16.33. Colgate-Palmolive Company has a 52 week low of $74.54 and a 52 week high of $99.33. The business’s 50 day moving average is $88.07 and its two-hundred day moving average is $87.04. The firm has a market cap of $73.66 billion, a price-to-earnings ratio of 35.82, a price-to-earnings-growth ratio of 4.85 and a beta of 0.33.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, May 1st. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03. The business had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.22 billion. Colgate-Palmolive had a return on equity of 386.76% and a net margin of 10.04%.The company’s revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.91 earnings per share. On average, research analysts predict that Colgate-Palmolive Company will post 3.81 EPS for the current year.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.3%. Colgate-Palmolive’s dividend payout ratio is 82.49%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CL shares. Wall Street Zen cut shares of Colgate-Palmolive from a “buy” rating to a “hold” rating in a report on Sunday, March 29th. Royal Bank Of Canada restated an “outperform” rating and issued a $102.00 target price on shares of Colgate-Palmolive in a report on Monday, May 4th. Piper Sandler dropped their target price on shares of Colgate-Palmolive from $96.00 to $92.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 8th. Barclays lifted their price target on shares of Colgate-Palmolive from $79.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Tuesday, May 5th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Colgate-Palmolive in a research note on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $95.88.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.